320
Participants
Start Date
April 30, 2006
Primary Completion Date
April 30, 2010
Study Completion Date
April 30, 2010
Erlotinib (Tarceva)
Erlotinib at the dose of 150 mg orally once a day continually until progression
Pemetrexed (Alimta)
Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks for 6 consecutive cycles
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli
401 Military Hospital, Medical Oncology Unit, Athens
Air Forces Military Hospital, Dep of Medical Oncology, Athens
IASO General Hospital of Athens, 1st Department of Medical Oncology, Athens
Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens
Sismanogleio General Hospital, 1st, 2nd Department of Pulmonary Diseases, Athens
Sotiria General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases, Athens
Metaxa's Anticancer Hospital of Piraeus,1st Dep of Medical Oncology, Piraeus
Theagenion Anticancer Hospital of Thessaloniki, Thessaloniki
Lead Sponsor
University Hospital of Crete
OTHER
Hellenic Oncology Research Group
OTHER